Patient P-02381
Therapy response
Declining
Tolerance
Favorable
GI state
Improving
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
66%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 66 SC-12 recommended — Supportive Compound SC-12
- Day 67 Patient accepted — Started SC-12 in the companion
- Day 73 GI symptom burden −17% vs expected — Supportive Compound SC-12
- Day 74 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 78 GI-04 recommended — GI Support Protocol GI-04
- Day 79 Patient accepted — Started GI-04 in the companion
- Day 79 Tolerance state changed — Unstable → Improving
- Day 87 No meaningful change — GI Support Protocol GI-04
What changed?
Trajectory began diverging from predicted response on Day 74.
Primary contributors, last 14 days
- Treatment adherence-12
- GI instability-8
- Toxicity-4
What helped?
- Supportive Compound SC-12Day 66Result: symptom burden −17%
- GI Support Protocol GI-04Day 78Result: no meaningful change
LIFE OS recommendation
Monitoring Escalation ME-01
75%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 58 and rising
- WearableSleep 5.9 h, below personal baseline
- Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 53
- WearableHRV 18 ms, trending down
- Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
- Autonomic recovery ↑40
- Wearable2,661 steps/day
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.6 · butyrate capacity 48/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 17 ms
- Sleep
- 5.9 h
- Steps
- 2,640
- Resting HR
- 66 bpm
Daily log: GI score 58, nutritional resilience 38, adherence 51.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02508 | 53% | S14 | ME-01 | improved | 51 |
| P-02244 | 45% | S14 | GI-04 | improved | 46 |
| P-02236 | 43% | S14 | GI-04 | improved | 45 |
| P-02409 | 42% | S01 | SC-12 | no change | 54 |
| P-02132 | 41% | S14 | SC-12 | improved | 40 |
| P-02165 | 40% | S14 | ME-01 | improved | 59 |
| P-02209 | 40% | S12 | GI-04 | improved | 36 |
| P-02574 | 39% | S14 | ME-01 | improved | 45 |
| P-02149 | 38% | S14 | GI-04 | improved | 50 |
| P-02216 | 38% | S11 | GI-04 | improved | 53 |
| P-02643 | 38% | S14 | SC-12 | improved | 46 |
| P-02693 | 38% | S14 | ME-01 | improved | 41 |